Longjin Pharmaceutical(SZ:002750)2022-12-06 01:28Group 1: Market Overview - The market share of the current herbal medicine products related to "Deng Zhan Hua" is approximately 1.99%, with hospital coverage only at 15% to 20%, indicating significant potential for future market expansion [3] - The main competitors in the "Deng Zhan Hua" product segment are Longjin Pharmaceutical, Hunan Hengsheng, and Biovale, although they produce different formulations [3] Group 2: Product Confidence and Quality Control - The company's confidence in its products stems from strict quality control measures, including advanced equipment and meticulous processes from cultivation to packaging [3] - The company adheres to national new drug application standards, conducting pharmacological and toxicological research, and has completed clinical phase IV safety and efficacy evaluations [3] Group 3: Product Positioning and Marketing - The injectable "Deng Zhan Hua" product is currently included in the national medical insurance catalog but has not yet entered the national essential drug list; it is included in local essential drug supplements in Yunnan, Shandong, and Henan [4] - The marketing strategy primarily focuses on academic promotion, with provincial managers and agents working in tandem, supported by a team of experts conducting nationwide academic training [4] Group 4: Financial Performance and Goals - The company's revenue target for the year aligns with the third-quarter report, with a projected fluctuation of approximately 10% to 60% [4] - The profit growth reported in the third quarter is mainly attributed to the disposal of subsidiary investments and increased returns from financial products [4] Group 5: Strategic Decisions - The company has decided to transfer all equity of its subsidiary Beijing Kechuang due to its low relevance to the main business and the high costs associated with necessary upgrades to meet market demands [5]